| SLB |
Report |
Revenue |
IN-LINE |
pred ~$8.74B vs. cons $8.69B |
MEDIUM |
| SLB |
Report |
Adjusted EPS |
BEAT |
pred ~$0.53 vs. cons $0.52 |
MEDIUM |
| SLB |
Report |
Adjusted EBITDA |
BEAT |
pred ~$1.82B vs. cons $1.80B |
LOW |
| SLB |
Guide |
Q3 2026 revenue |
LOWER |
guide ~$8.85B vs. cons $9.10B (Q3 2026) |
MEDIUM |
| SLB |
Guide |
Q3 2026 adjusted EPS |
LOWER |
guide ~$0.58 vs. cons $0.66 (Q3 2026) |
MEDIUM |
| SLB |
Guide |
Second-half adjusted EPS |
LOWER |
guide ~$1.31 vs. cons $1.48 (H2 2026) |
LOW |
| SLB |
Guide |
Share repurchases |
UNCHANGED |
guide ~$2.40B vs. cons $2.40B (FY 2026) |
MEDIUM |
| SLB |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.8% |
— |
MEDIUM |
| SLB |
Return |
5-day cumulative residual |
-4.3% (FOLLOW-THROUGH) |
A modest Q2 beat is outweighed by renewed Middle East disruption driving Q3 adjusted EPS toward ~$0.58 versus $0.66 consensus and H2 adjusted EPS toward ~$1.31 versus $1.48 consensus; estimate cuts should continue after the call. |
MEDIUM |